Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models

Irene H. Cheng, Kimberly Scearce-Levie, Justin Legleiter, Jorge J. Palop, Hilary Gerstein, Nga Bien-Ly, Jukka Puoliväli, Sylvain Lesné, Karen H. Ashe, Paul J. Muchowski, Lennart Mucke

Research output: Contribution to journalArticle

298 Citations (Scopus)

Abstract

Many proteins suspected of causing neurodegenerative diseases exist in diverse assembly states. For most, it is unclear whether shifts from one state to another would be helpful or harmful. We used mutagenesis to change the assembly state of Alzheimer disease (AD)-associated amyloid-β (Aβ) peptides. In vitro, the "Arctic" mutation (AβE22G) accelerated Aβ fibrillization but decreased the abundance of nonfibrillar Aβ assemblies, compared with wild-type Aβ. In human amyloid precursor protein (hAPP) transgenic mice carrying mutations adjacent to Aβ that increase Aβ production, addition of the Arctic mutation markedly enhanced the formation of neuritic amyloid plaques but reduced the relative abundance of a specific nonfibrillar Aβ assembly (Aβ*56). Mice overexpressing Arctic mutant or wild-type Aβ had similar behavioral and neuronal deficits when they were matched for Aβ*56 levels but had vastly different plaque loads. Thus, Aβ*56 is a likelier determinant of functional deficits in hAPP mice than fibrillar Aβ deposits. Therapeutic interventions that reduce Aβ fibrils at the cost of augmenting nonfibrillar Aβ assemblies could be harmful.

Original languageEnglish (US)
Pages (from-to)23818-23828
Number of pages11
JournalJournal of Biological Chemistry
Volume282
Issue number33
DOIs
StatePublished - Aug 17 2007

Fingerprint

Oligomers
Amyloid
Alzheimer Disease
Amyloid beta-Protein Precursor
Amyloid Plaques
Mutation
Mutagenesis
Neurodegenerative Diseases
Transgenic Mice
Neurodegenerative diseases
Peptides
Deposits
Proteins
Therapeutics

Cite this

Cheng, I. H., Scearce-Levie, K., Legleiter, J., Palop, J. J., Gerstein, H., Bien-Ly, N., ... Mucke, L. (2007). Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. Journal of Biological Chemistry, 282(33), 23818-23828. https://doi.org/10.1074/jbc.M701078200

Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. / Cheng, Irene H.; Scearce-Levie, Kimberly; Legleiter, Justin; Palop, Jorge J.; Gerstein, Hilary; Bien-Ly, Nga; Puoliväli, Jukka; Lesné, Sylvain; Ashe, Karen H.; Muchowski, Paul J.; Mucke, Lennart.

In: Journal of Biological Chemistry, Vol. 282, No. 33, 17.08.2007, p. 23818-23828.

Research output: Contribution to journalArticle

Cheng, IH, Scearce-Levie, K, Legleiter, J, Palop, JJ, Gerstein, H, Bien-Ly, N, Puoliväli, J, Lesné, S, Ashe, KH, Muchowski, PJ & Mucke, L 2007, 'Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models', Journal of Biological Chemistry, vol. 282, no. 33, pp. 23818-23828. https://doi.org/10.1074/jbc.M701078200
Cheng, Irene H. ; Scearce-Levie, Kimberly ; Legleiter, Justin ; Palop, Jorge J. ; Gerstein, Hilary ; Bien-Ly, Nga ; Puoliväli, Jukka ; Lesné, Sylvain ; Ashe, Karen H. ; Muchowski, Paul J. ; Mucke, Lennart. / Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. In: Journal of Biological Chemistry. 2007 ; Vol. 282, No. 33. pp. 23818-23828.
@article{f1ba8093fdaa4e16a34c7a861f67864e,
title = "Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models",
abstract = "Many proteins suspected of causing neurodegenerative diseases exist in diverse assembly states. For most, it is unclear whether shifts from one state to another would be helpful or harmful. We used mutagenesis to change the assembly state of Alzheimer disease (AD)-associated amyloid-β (Aβ) peptides. In vitro, the {"}Arctic{"} mutation (AβE22G) accelerated Aβ fibrillization but decreased the abundance of nonfibrillar Aβ assemblies, compared with wild-type Aβ. In human amyloid precursor protein (hAPP) transgenic mice carrying mutations adjacent to Aβ that increase Aβ production, addition of the Arctic mutation markedly enhanced the formation of neuritic amyloid plaques but reduced the relative abundance of a specific nonfibrillar Aβ assembly (Aβ*56). Mice overexpressing Arctic mutant or wild-type Aβ had similar behavioral and neuronal deficits when they were matched for Aβ*56 levels but had vastly different plaque loads. Thus, Aβ*56 is a likelier determinant of functional deficits in hAPP mice than fibrillar Aβ deposits. Therapeutic interventions that reduce Aβ fibrils at the cost of augmenting nonfibrillar Aβ assemblies could be harmful.",
author = "Cheng, {Irene H.} and Kimberly Scearce-Levie and Justin Legleiter and Palop, {Jorge J.} and Hilary Gerstein and Nga Bien-Ly and Jukka Puoliv{\"a}li and Sylvain Lesn{\'e} and Ashe, {Karen H.} and Muchowski, {Paul J.} and Lennart Mucke",
year = "2007",
month = "8",
day = "17",
doi = "10.1074/jbc.M701078200",
language = "English (US)",
volume = "282",
pages = "23818--23828",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "33",

}

TY - JOUR

T1 - Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models

AU - Cheng, Irene H.

AU - Scearce-Levie, Kimberly

AU - Legleiter, Justin

AU - Palop, Jorge J.

AU - Gerstein, Hilary

AU - Bien-Ly, Nga

AU - Puoliväli, Jukka

AU - Lesné, Sylvain

AU - Ashe, Karen H.

AU - Muchowski, Paul J.

AU - Mucke, Lennart

PY - 2007/8/17

Y1 - 2007/8/17

N2 - Many proteins suspected of causing neurodegenerative diseases exist in diverse assembly states. For most, it is unclear whether shifts from one state to another would be helpful or harmful. We used mutagenesis to change the assembly state of Alzheimer disease (AD)-associated amyloid-β (Aβ) peptides. In vitro, the "Arctic" mutation (AβE22G) accelerated Aβ fibrillization but decreased the abundance of nonfibrillar Aβ assemblies, compared with wild-type Aβ. In human amyloid precursor protein (hAPP) transgenic mice carrying mutations adjacent to Aβ that increase Aβ production, addition of the Arctic mutation markedly enhanced the formation of neuritic amyloid plaques but reduced the relative abundance of a specific nonfibrillar Aβ assembly (Aβ*56). Mice overexpressing Arctic mutant or wild-type Aβ had similar behavioral and neuronal deficits when they were matched for Aβ*56 levels but had vastly different plaque loads. Thus, Aβ*56 is a likelier determinant of functional deficits in hAPP mice than fibrillar Aβ deposits. Therapeutic interventions that reduce Aβ fibrils at the cost of augmenting nonfibrillar Aβ assemblies could be harmful.

AB - Many proteins suspected of causing neurodegenerative diseases exist in diverse assembly states. For most, it is unclear whether shifts from one state to another would be helpful or harmful. We used mutagenesis to change the assembly state of Alzheimer disease (AD)-associated amyloid-β (Aβ) peptides. In vitro, the "Arctic" mutation (AβE22G) accelerated Aβ fibrillization but decreased the abundance of nonfibrillar Aβ assemblies, compared with wild-type Aβ. In human amyloid precursor protein (hAPP) transgenic mice carrying mutations adjacent to Aβ that increase Aβ production, addition of the Arctic mutation markedly enhanced the formation of neuritic amyloid plaques but reduced the relative abundance of a specific nonfibrillar Aβ assembly (Aβ*56). Mice overexpressing Arctic mutant or wild-type Aβ had similar behavioral and neuronal deficits when they were matched for Aβ*56 levels but had vastly different plaque loads. Thus, Aβ*56 is a likelier determinant of functional deficits in hAPP mice than fibrillar Aβ deposits. Therapeutic interventions that reduce Aβ fibrils at the cost of augmenting nonfibrillar Aβ assemblies could be harmful.

UR - http://www.scopus.com/inward/record.url?scp=34548258322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548258322&partnerID=8YFLogxK

U2 - 10.1074/jbc.M701078200

DO - 10.1074/jbc.M701078200

M3 - Article

C2 - 17548355

AN - SCOPUS:34548258322

VL - 282

SP - 23818

EP - 23828

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 33

ER -